SC 13G: OnKure Therapeutics, Inc.
Ticker: OKUR · Form: SC 13G · Filed: Oct 11, 2024 · CIK: 1637715
Sentiment: neutral
Topics: sc-13g
AI Summary
SC 13G filing by OnKure Therapeutics, Inc..
Risk Assessment
Risk Level: low
Filing Stats: 1,414 words · 6 min read · ~5 pages · Grade level 10.1 · Accepted 2024-10-11 16:00:04
Key Financial Figures
- $0.0001 — me of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securiti
Filing Documents
- deeptrack-okur100424.htm (SC 13G) — 99KB
- 0001172661-24-004242.txt ( ) — 101KB
(a)Name of Issuer
Item 1. (a)Name of Issuer ONKURE THERAPEUTICS, INC.
(b)Address of Issuer’s Principal
Item 1. (b)Address of Issuer’s Principal Executive Offices 6707 Winchester Circle, Suite 400 Boulder, Colorado 80301
(a)Names of Persons Filing
Item 2. (a)Names of Persons Filing: (i) Deep Track Capital, LP (ii) Deep Track Biotechnology Master Fund, Ltd. (iii) David Kroin
( b)Address
Item 2. ( b)Address of Principal Business Office: (i) 200 Greenwich Ave, 3rd Floor, Greenwich, CT 06830 (ii) c/o Walkers Corporate Limited, 190 Elgin Ave, George Town, KY1-9001, Cayman Islands (iii) c/o Deep Track Capital, LP, 200 Greenwich Ave, 3rd Floor, Greenwich, CT 06830
(c) Citizenship
Item 2. (c) Citizenship: (i) Delaware (ii) Cayman Islands (iii) United States
(d)Title of Class of Securities
Item 2. (d)Title of Class of Securities Common Stock, par value $0.0001 per share (the “Common Stock”)
(e) CUSIP No
Item 2. (e) CUSIP No.: 68277Q105 CUSIP No. 68277Q105 SCHEDULE 13G Page 6 of 9 Pages
If
Item 3.If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: (a) Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o); (b) Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c); (c) Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c); (d) Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8); (e) o An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E); (f) An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F); (g) A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G); (h) A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); (j) A non-U.S. institution in accordance with 240.13d-1(b)(1)(ii)(J); (k) A group, in accordance with 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with 240.13d-1(b)(1)(ii)(J), please specify the type of institution: Not Applicable CUSIP No. 68277Q105 SCHEDULE 13G Page 7 of 9 Pages Item 4.Ownership Information with respect to the Reporting Persons' ownership of the Common Stock as of October 11, 2024, is incorporated by reference to items (5) - (9) and (11) of the cover page of the respective Reporting Person. The amount beneficially owned by each Reporting Person is determined based on 12,652,811 Class A Common Stock as of October 4, 2024, according to the issuer’s Form 8-K filed with the SEC on October 8, 2024. Item 5.Ownership of Five Percent or Less of a Class If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial